form8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 21, 2009
Commission File No. 000-16929
DOR BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
|
DELAWARE |
|
41-1505029 |
|
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
| |
|
|
|
29 Emmons Drive, Suite C-10
Princeton, NJ |
|
08540 |
|
(Address of principal executive offices) |
|
(Zip Code) |
| |
(609) 538-8200 |
|
| |
(Issuer’s telephone number, including area code) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On September 21, 2009, DOR BioPharma, Inc. (the “Company”) issued a press release announcing the receipt of a $9.4 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The
grant will fund, over a five-year period, the development of formulation and manufacturing processes for vaccines, including RiVaxTM, that are stable at elevated temperatures. The grant will also fund the development of improved thermostable adjuvants expected to result in rapidly acting vaccines that can be given with fewer injections over shorter intervals. A copy of the press release is attached as Exhibit 99.1
to this report.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Title
99.1 Press release issued by the Company on September 21, 2009.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DOR BIOPHARMA, INC.
|
September 21, 2009 |
by: |
/s/ Christopher J. Schaber |
| |
|
Christopher J. Schaber, Ph.D. |
| |
|
President and Chief Executive Officer |
| |
|
(Principal Executive Officer) |
| |
|
|
EXHIBIT INDEX
Exhibit No. Description
99.1 Press release issued by the Company on September 21, 2009.